Telmisartan is an ARB used to treat hypertension, diabetic nephropathy, and congestive heart failure. Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.
- Mechanism
- Curator reviewed · 2 references
Telmisartan interferes with the binding of angiotensin II to the angiotensin II AT1-receptor by binding reversibly and selectively to the receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. Telmisartan does not inhibit the angiotensin converting enzyme, other hormone receptors, or ion channels. Studies also suggest that telmisartan is a partial agonist of PPARγ, which is an established target for antidiabetic drugs. This suggests that telmisartan can improve carbohydrate and lipid metabolism, as well as control insulin resistance without causing the side effects that are associated with full PPARγ activators.
- Primary indication
- Used alone or in combination with other classes of antihypertensives for the treatment of hypertension..Curator reviewed · 9 structured indications
- Formula / weight
- C33H30N4O2 · 514.6169 g/mol (avg)
- First approval
- Canada, 1999 · United States, 2000 · European Union, 2016
- Code names
- BIBR-277 · BIBR 277 SE
- Brand names
Resolves to
RMMXLENWKUUMAY-UHFFFAOYSA-NSMILESCCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Telmisartan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account